Immunohistochemical analyses and exomic sequencing are considered the gold standard for determining IDH mutation status in gliomas [9,10]; however, several factors, such as tissue heterogeneity, partial sampling of tissue specimens, and presence of variable amounts of antigens constrain the utility of these methods in reliable detection of IDH mutation status [11]. The gene discussed is IDH2; the disease is central nervous system cancer.